21

22
Baogen Wu, Yun He, Truc Ngoc Nguyen, Kelli L Kuhen, David Archer Ellis, Tao Jiang, Xiaohui He, Kunyong Yang, Badry Bursulaya: Pyrrolidones with anti-HIV activity. IRM, Emily Tongco Wu, Genomics Institute of the Novartis Research Foundation, October 13, 2009: US07601742

The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of p ...


23

24
Valentina Molteni, Xiaolin Li, Juliet Nabakka, David Archer Ellis, Beth Anaclerio, Enrique Saez, John Wityak: Compounds and compositions as LXR modulators. Daniel E Raymond, Genomiccs Institute of the Novartis Research Foundation, October 29, 2013: US08569345

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).


25
Valentina Molteni, Xiaolin Li, Juliet Nabakka, David Archer Ellis, Beth Anaclerio, Enrique Saez, John Wityak: Compounds and compositions as LXR modulators. Hamilton, Daniel E Raymond, Genomics Institute of the Novartis Research Foundation, April 17, 2012: US08158662

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).


26
Yun He, David Archer Ellis, Beth Marie Anaclerio, Kelli L Kuhen, Baogen Wu, Tao Jiang: Quinolones with anti-HIV activity. IRM, Morgan Lewis & Bockius, March 28, 2006: US07019141

The present invention relates to inhibition of viruses, e.g., HIV using quinolones and compounds related to quinolones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of proph ...


27
David Archer Ellis, Lukas Scheibler, Najam A Sharif: Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension. Novartis, Mark Flanigan, March 28, 2017: US09604949

Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such co ...


28
Liu Hong, He Xiaohui, Choi Ha Soon, Yang Kunyong, Woodmansee David, Wang Zhicheng, Ellis David Archer, Wu Baogen, He Yun, Nguyen Truc Ngoc: Composes et compositions servant dinhibiteurs dactivite de recepteur cannabinoide de type 1, Compounds and compositions as inhibitors of cannabinoid receptor 1 activity. Irm, Irm, Fetherstonhaugh & Co, October 25, 2011: CA2581225

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).


29
He Xiaohui, Yang Kunyong, Liu Hong, Ellis David Archer: Composes et compositions utilises comme inhibiteurs de lactivite du recepteur cannabinoide de type 1, Compounds and compositions as inhibitors of cannabinoid receptor 1 activity. Irm, Irm, Fetherstonhaugh & Co, May 24, 2011: CA2645967

The invention provides compounds of formula (Ia), (Ic), (Ig) and (Ik), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).


30